Syngene reported a steady growth number for the March-ended quarter. While the management guided FY22 topline growth in the mid-teens, net profit growth is expected to be mediocre as the company continues to invest heavily in skill resources and R&D facilities.
Capex investment could be in the range of Rs 750-900 crore during the current financial year. The company also plans to add about 20 percent of strength for scientists. While these investments are necessary for the long term, an uptick in growth numbers could be seen as early as FY23 onwards.
In the special segment ‘Moneycontrol Pro Ideas For Profit’, moneycontrol.com’s Anubhav Sahu gets more details on the company’s performance.
Watch the video for more.Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.